Online inquiry

IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ656MR)

This product GTTS-WQ656MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets AOC3 gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001277731.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8639
UniProt ID Q16853
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ656MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11299MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-522
GTTS-WQ7891MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ2688MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ2046MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ8727MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ15764MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ8253MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ4930MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW